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A B S T R A C T
Background
Venous thromboembolism (VTE) is a serious but preventable cause of morbidity and mortality. Neuromuscular electrical stimulation
systems (NMES) for the prevention of VTEmay be beneficial for patients in whom pharmacological or standard mechanical prophylaxis
methods are contraindicated or are regarded as unsafe or impractical. Although findings of experimental studies suggest that NMES
reduce venous stasis, the clinical utility and effectiveness of NMES in VTE prevention remain controversial.
Objectives
To assess the effectiveness of neuromuscular electrical stimulation in the prevention of venous thromboembolism.
Search methods
The Cochrane Vascular Group Information Specialist (CIS) searched the Specialised Register (22 March 2017) and the Cochrane
Central Register of Controlled Studies (CENTRAL (2017, Issue 2)). The CIS also searched trial registries for details of ongoing and
unpublished studies. The review authors searched the bibliographic lists of relevant articles and reviews to look further for potentially
eligible trials.
Selection criteria
We planned to include randomised controlled trials (RCTs) and quasi-randomised trials that compared any form of neuromuscular
electrical stimulation as an intervention for VTE prophylaxis (alone or combined with pharmacological or other mechanical methods)
versus no prophylaxis and other mechanical or pharmacological methods of VTE prophylaxis.
Data collection and analysis
At least two independent review authors were involved in study selection, data extraction, methodological quality assessment of included
studies, and data analysis. We resolved disagreements by discussion between the two review authors. If no agreement could be reached,
a third review author acted as an adjudicator. The main outcomes of the review were total deep vein thrombosis (DVT), symptomatic
and asymptomatic DVT, pulmonary embolism (PE), total VTE and bleeding (major and minor). The quality of evidence was assessed
using the GRADE approach and is indicated in italics.
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Main results
We included in the review five randomised controlled trials and three quasi-randomised trials, enrolling a total of 904 participants.
Among these, four studies included patients undergoing major surgical procedures; one study included patients undergoing surgery for
hip fracture under spinal anaesthesia; one study included trauma patients with a contraindication for prophylactic heparin; one study
included neurosurgical patients who were operated on under general anaesthesia; and one study included patients with non-functional
spinal cord injuries. Overall, eight studies investigated 22 treatment arms. Four studies compared the NMES arm with a no prophylaxis
arm, and five studies compared the NMES arm with alternative methods of prophylaxis arms. Alternative methods of prophylaxis
included low-dose heparin (5000 IU subcutaneously) - two studies, Dextran 40 - one study, graduated compression stockings (GCS)
and intermittent pneumatic compression devices (IPCD) - one study. One study compared combined NMES and low-dose heparin
versus no prophylaxis or low-dose heparin alone.
We found no clear difference in risks of total DVT (odds ratio (OR) 1.01, 95% confidence interval (CI) 0.60 to 1.70, P = 0.98; 6
studies, 415 participants; low-quality evidence), asymptomatic DVT (OR 1.61, 95% CI 0.40 to 6.43, P = 0.50; 1 study, 89 participants;
low-quality evidence), symptomatic DVT (OR 0.40, 95% CI 0.02 to 10.07, P = 0.58; 1 study, 89 participants; low-quality evidence), PE
(OR 1.31, 95% CI 0.38 to 4.48, P = 0.67; 2 studies, 126 participants;low-quality evidence), and total VTE (OR 0.92, 95% CI 0.34 to
2.52, P = 0.88; 1 study, 72 participants; low-quality evidence) between prophylaxis with NMES and alternative methods of prophylaxis.
None of the studies in this comparison reported bleeding.
Compared with no prophylaxis, NMES showed lower risks of total DVT (OR 0.40, 95% CI 0.23 to 0.70, P = 0.02; 4 studies, 576
participants; moderate-quality evidence) and total VTE (OR 0.23, 95% CI 0.09 to 0.59, P = 0.002; 1 study, 77 participants; low-
quality evidence). Data show no clear differences in risk of asymptomatic DVT (OR 0.32, 95% CI 0.06 to 1.62, P = 0.17; 1 study, 200
participants; low-quality evidence), symptomatic DVT (OR 0.06, 95% CI 0.00 to 1.36, P = 0.08; 1 study, 160 participants;low-quality
evidence), or PE (OR 0.36, 95% CI 0.12 to 1.07, P = 0.07; 1 study, 77 participants; low-quality evidence) between prophylaxis with
NMES and no prophylaxis. None of the studies in this comparison reported bleeding.
In comparison with low-dose heparin, NMES was associated with higher risk of total DVT (OR 2.78, 95% CI 1.19 to 6.48, P = 0.02;
2 studies, 194 participants; low-quality evidence), but data were inadequate for other comparisons (NMES vs Dextran 40, NMES vs
GCS, or NMES vs IPCD) and for other clinical outcomes such as symptomatic or asymptomatic DVT, PE, total VTE, and bleeding
in individual comparisons.
Overall, we judged the quality of available evidence to be low owing to high or unclear risk of bias and imprecise effect estimates due
to small numbers of studies and events.
Authors’ conclusions
Low-quality evidence shows no clear difference in the risk of DVT between NMES and alternative methods of prophylaxis but suggest
that NMES may be associated with lower risk of DVT compared with no prophylaxis (moderate-quality evidence) and higher risk of
DVT compared with low-dose heparin (low-quality evidence). The best available evidence about the effectiveness of NMES in the
prevention of VTE is not adequately robust to allow definitive conclusions. Adequately powered high-quality randomised controlled
trials are required to provide adequately robust evidence.
P L A I N L A N G U A G E S U M M A R Y
Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Background
Formation of unwanted blood clots in the deep veins of the legs is a serious and potentially fatal health problem because blood clots
in the legs can travel to the lungs and cause death. Unwanted blood clots in legs can occur as the result of reduced mobility (due
to surgery, stroke, injuries, etc.), increased tendency for blood clotting (due to cancer, inherited conditions, etc.), and other factors.
Formation of unwanted blood clots in the legs can be prevented by pharmacological methods (heparin, warfarin, etc.) or mechanical
methods (specific stockings or devices that help to compress the legs to promote flow of blood within the veins, reducing the risk of
blood clotting). Neuromuscular electrical stimulation systems (NMES) deliver electrical impulses via electrodes to the skin over selected
muscle groups or nerves to induce an involuntary muscle contraction. NMES are thought to be effective as a mechanical method of
preventing blood clots in the legs. Therefore, we aimed to identify available evidence on the effectiveness of NMES compared with
other methods in preventing formation of unwanted blood clots.
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Study characteristics and key results
We identified eight studies (current until 22 March 2017) enrolling a total of 904 participants that compared NMES with no treatment
or with other methods for preventing blood clots, such as low-dose heparin and compression stockings. We found no clear difference
in the risk of unwanted blood clots in the legs between NMES and alternative methods of blood clot prevention. We also found that
NMES is associated with lower risk of formation of unwanted blood clots in the legs when compared with no treatment, but higher
risk of unwanted blood clot formation when compared with heparin. Additional studies are required to obtain stronger evidence.
Quality of the evidence
Overall, the quality of available evidence is low and has been downgraded owing to high or unclear risk of bias, differences between
studies, and imprecise effect estimates due to small numbers of studies and events.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
NMES compared to alternat ive prophylaxis for the prevent ion of venous thromboembolism
Patient or population: part icipants at risk of venous thromboembolism
Setting: hospital, secondary care
Intervention: NMES
Comparison: alternat ive prophylaxis
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with alternative
prophylaxis
Risk with NMES
Total DVT
Follow-up: mean 11
days
Study populat ion OR 1.01
(0.60 to 1.70)
415
(6 RCTs)
⊕⊕©©
LOWa,b
170 per 1000 172 per 1000
(110 to 259)
Asymptomatic DVT
Follow-up: 8 days
Study populat ion OR 1.61
(0.40 to 6.43)
89
(1 RCT)
⊕⊕©©
LOWa,c
82 per 1000 125 per 1000
(34 to 364)
Symptomatic DVT
Follow-up: 8 days
Study populat ion OR 0.40
(0.02 to 10.07)
89
(1 RCT)
⊕⊕©©
LOWa,c
20 per 1000 8 per 1000
(0 to 173)
PE
Follow-up: mean 4 days
Study populat ion OR 1.31
(0.38 to 4.48)
126
(2 RCTs)
⊕⊕©©
LOWa,c
70 per 1000 90 per 1000
(28 to 253)
Total VTE
Follow-up: 6 days
Study populat ion OR 0.92
(0.34 to 2.52)
72
(1 RCT)
⊕⊕©©
LOWa,c
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314 per 1000 297 per 1000
(135 to 536)
Bleeding (major and mi-
nor)
see comment see comment not est imable 415
(6 RCTs)
- None of the studies
in this comparison re-
ported this outcome
*Assumed control intervent ion risks were calculated by the mean number of events in control groups of selected studies for each outcome. The risk in the intervention group
(and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; NMES: neuromuscular electrical st imulat ion; OR: odds rat io; PE: pulmonary embolism; RCT: randomised controlled trial;
VTE: venous thromboembolism
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aHigh or unclear risk of select ion bias, performance bias, and detect ion bias - downgraded by one level.
bModerate level of between-study heterogeneity - downgraded by one level.
cFew part icipants and few events and thus wide conf idence intervals - downgraded by one level.
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B A C K G R O U N D
Description of the condition
Venous thromboembolism (VTE) is a serious but preventable
cause of morbidity and mortality (Arnold 2001), that occurs in
approximately 1 per 1000 adults each year (White 2003). Clinical
manifestations of VTE - deep vein thrombosis (DVT) and pul-
monary embolism (PE) with or without DVT - constitute two-
thirds and one-third of cases of VTE, respectively (White 2003).
Endothelial injury, hypercoagulable state, and stasis, known asVir-
chow’s triad, form the basis for the pathogenesis of VTE (Virchow
1856). Risk factors contributing to the development of VTE may
be hereditary or acquired, and modifiable (e.g. obesity, surgery,
trauma, immobility, malignancy) or non-modifiable (e.g. paraple-
gia, hereditary thrombophilia such as factor V Leiden) (Anderson
2003; Cushman 2007). Hospitalisation is associated with in-
creased risk of VTE due to the presence of multiple risk factors
such as immobility, malignancy, infection, and surgery (Anderson
1992). Prophylaxis against VTE is very important for most hos-
pitalised patients, in particular, patients in surgical, trauma, and
intensive care units (ICUs), who are at higher risk of VTE as they
are more likely to be immobile and to be exposed to the afore-
mentioned VTE risk factors (Guyatt 2012).
Description of the intervention
Mechanical methods of prophylaxis include graduated compres-
sion stockings (GCS), intermittent pneumatic compression de-
vices (IPCD), and neuromuscular electrical stimulation systems
(NMES) (Roderick 2005). GCS and IPCDhave been shown to be
effective in VTE prophylaxis (Pavon 2016; Sachdeva 2014). How-
ever, despite their effectiveness and common use, these methods
may be associated with poor patient compliance due to discom-
fort, excessive heat, itchiness, sweating under the inflatable cuffs,
and the potential for peroneal nerve palsy (Faghri 1997; Froimson
2009; Kahn 2002; Laverick 1990; Masri 2004). Neuromuscular
electrical stimulation systems deliver electrical energy to skeletal
muscle nerve branches, then to muscle units, via superficial elec-
trodes attached to the skin (Baker 1993).Neuromuscular electrical
stimulation systems for the prevention of VTE may be beneficial
for patients for whom pharmacological or standard mechanical
methods of prophylaxis are contraindicated or are regarded as un-
safe or impractical.
In terms of limitations, NMES may induce excessive neuromus-
cular fatigue (Gorgey 2009). Also, muscle contractions induced
by NMES are not as unsynchronised and may not be as effective as
voluntary muscle contractions. Considering the resistance created
by the viscosity of subcutaneous tissue, activation of deeper struc-
tures with standard surface stimulation is usually limited (Doucet
2012). Therefore, ideal delivery settings (frequency, energy, etc.)
remainunknown.Moreover, althoughmoderndevices are thought
to be associated with better tolerability, older NMES delivery sys-
tems produced painful stimuli, so they could be used only during
general anaesthesia (Nicolaides 2013). Owing to lack of compara-
tive data, it is unclear whether NMES would result in better com-
pliance than other methods of mechanical prophylaxis.
How the intervention might work
Experimental studies have shown that NMES increase venous
blood velocity and blood flow in stimulated legs, thus reducing ve-
nous stasis (Breen 2012; Broderick 2010; Broderick 2013; Griffin
2010; Izumi 2010; Lyons 2002; Moloney 2006; Tucker 2010;
Warwick 2013). Although the use of venous velocity as a surrogate
outcome for VTE incidence is controversial, this effect may prove
beneficial in VTE prevention (Morris 2004). Moreover, neural
supply to the veins provides direct antithrombotic effects as the
fourth factor not included in Virchow’s triad; NMES, via neu-
rogenic pathways, may influence this fourth factor and suppress
thrombogenesis (Stefanou 2016). Findings of experimental stud-
ies suggest acceptable tolerability of NMES that can potentially
lead to good patient compliance (Broderick 2010; Broderick 2013;
Moloney 2006; Warwick 2013).
Why it is important to do this review
Although findings of experimental studies suggest that NMES re-
duce venous stasis, the clinical utility and effectiveness ofNMES in
VTEprevention remain controversial (Hajibandeh 2015). This re-
view of clinical trials investigating NMES as a mechanical method
for VTE prevention will help to address current uncertainties
about the benefits of NMES for different patient groups.
A glossary of terms is provided in Appendix 1 to help clarify some
of the terms used.
O B J E C T I V E S
To assess the effectiveness of neuromuscular electrical stimulation
in the prevention of venous thromboembolism.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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Randomised controlled trials (RCTs) and quasi-randomised trials
that investigate any form of neuromuscular electrical stimulation
as an intervention for VTE prophylaxis.
Types of participants
Patients undergoing any form of neuromuscular electrical stimu-
lation for the purpose of VTE prevention.
Types of interventions
Intervention of interest
• Any form of neuromuscular electrical stimulation used
alone or combined with pharmacological or mechanical methods
of VTE prophylaxis, or both.
Comparison
• Mechanical methods of VTE prevention (including GCS or
IPCD), pharmacological VTE prophylaxis (including
anticoagulant or antithrombotic drugs), both mechanical and
pharmacological prophylaxis, or no prophylaxis.
Types of outcome measures
Primary outcomes
• Incidence of DVT (asymptomatic or symptomatic)
• Incidence of PE (with or without DVT)
• Incidence of total VTE (fatal and non-fatal)
• Bleeding (major and minor)
Secondary outcomes
• Device-related adverse effects such as skin irritation or
inflammation
• Physiological measurements including changes in tissue
oxygen levels, oxygen saturation, heart rate, and blood pressure
• Patient compliance
• Subjective discomfort measured by visual analogue scale
(VAS) scores and verbal rating scores (VRS)
• Freedom from VTE at 90 days (symptomatic or
asymptomatic)
Diagnosis of PE should be made by ventilation-perfusion scan,
computed tomography, pulmonary angiography, or autopsy.DVT
should be diagnosed by duplex ultrasonography, venography, or a
fibrinogen uptake test.
Major bleeding was defined as fatal bleeding; retroperitoneal, in-
tracranial, or intraocular bleeding; bleeding that causes haemo-
dynamic compromise, a decrease in haemoglobin of 3 g/dL or
more, or a decrease in haematocrit of 10% or more; or bleeding
that requires intervention or any transfusion of more than 1 unit
of packed red blood cells or whole blood. Minor bleeding is de-
fined as gross haematuria, gastrointestinal haemorrhage, haemop-
tysis, subconjunctival haemorrhage, or epistaxis; haematoma that
is larger than 5 cm or leads to prolonged or new hospitalisation;
or bleeding that causes a decrease in haemoglobin of 2 to 3 g/dL
(Mehran 2011).
Search methods for identification of studies
Electronic searches
The Cochrane Vascular Group Information Specialist (CIS)
searched the Specialised Register (22 March 2017) and the
Cochrane Central Register of Controlled Trials (CENTRAL;
2017, Issue 2) via the Cochrane Register of Studies (CRS) (http:/
/www.metaxis.com/CRSWeb/Index.asp). See Appendix 2 for de-
tails of the search strategy used to search the CRS. The Specialised
Register is maintained by the CIS and is constructed from weekly
electronic searches of MEDLINE, Embase, the Cumulative Index
toNursing andAlliedHealth Literature (CINAHL), and theAllied
and Complementary Medicine Database (AMED), and through
handsearching of relevant journals. The full list of databases, jour-
nals, and conference proceedings that have been searched, as well
as the search strategies used, is presented in the Specialised Register
section of the Cochrane Vascular Module in the Cochrane Library
(www.cochranelibrary.com).
In addition, the CIS searched the following trial databases for
details of ongoing and unpublished studies.
• World Health Organization International Clinical Trials
Registry (http://apps.who.int/trialsearch/).
• ClinicalTrials.gov (http://clinicaltrials.gov/).
• International Standard Registered Clinical/social sTudy
Number (ISRCTN) Register (http://www.isrctn.com/).
Searching other resources
We searched the bibliographic lists of relevant articles and reviews
for further potentially eligible trials. We contacted manufacturer
of the geko™ device (Sky Medical Technology Ltd, Newport,
Vermont, USA) for relevant trials.
Data collection and analysis
Selection of studies
Two review authors (ShahabH, ShahinH) independently assessed
the title and abstract of articles identified through the literature
searches.We retrieved the full texts of relevant reports and selected
articles that met the eligibility criteria of our review. We resolved
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discrepancies in study selection through discussion between review
authors. We consulted a third review author (GA) in the event of
disagreement.
Data extraction and management
We created an electronic data extraction spreadsheet consistent
with the Cochrane data collection form for intervention reviews.
We pilot-tested the spreadsheet in randomly selected articles and
adjusted it as needed. Our data extraction spreadsheet included
the following.
• Study-related data (first author, year of publication, country
of origin of the corresponding author, journal in which the study
was published, study design, study size, clinical condition of
study participants, type of intervention, duration of VTE
prophylaxis, and information about NMES including type of
device, frequency, pulse width, charge, and voltage).
• Baseline demographic and clinical information of trial
populations.
• Primary and secondary outcome data.
Two review authors (Shahab H, Shahin H) independently col-
lected and recorded data on the data extraction spreadsheet and
resolved disagreements by discussion. If no agreement could be
reached, we consulted a third review author (JS).
Assessment of risk of bias in included studies
We used the Cochrane tool for assessing risk of bias (Higgins
2011). Two review authors (Shahab H, Shahin H) independently
assessed each included study for risk of bias. We assessed all do-
mains (selection bias, performance bias, detection bias, attrition
bias, reporting bias, and other sources of bias), and for each indi-
vidual domain, we classified studies as having low, unclear, or high
risk of bias. We resolved disagreements by discussion between the
two review authors (Shahab H, Shahin H). If no agreement could
be reached, a third review author (FT) acted as an adjudicator.
Measures of treatment effect
The primary outcomes in our review (frequency of DVT, PE,
VTE, bleeding, and device-related adverse effects) were dichoto-
mous variables; therefore, we calculated the odds ratio (OR),which
represents the odds of an adverse event in the NMES group com-
pared with the non-NMES group, as the summary measure. An
OR of less than one would favour the NMES. For continuous
parameters such as compliance and discomfort measurements, we
planned to calculate the mean difference (MD) between NMES
and non-NMES groups, unless trials reported different scales of
measurement, in which case we planned to compute the standard-
ised mean difference (SMD).
Unit of analysis issues
Weused the individual patient as the unit of analysis in our review.
If any included study in our review reported outcomes related to a
mixture of units of analysis, we extracted only data relevant to our
unit of analysis. We excluded studies that randomised individual
legs instead of individual participants, as we believe that two legs
of one participant are not independent.
Dealing with missing data
We recorded information about dropouts and withdrawals and
other missing data; if not reported, we contacted study authors to
ask for this information. The final analysis was based on intention-
to-treat data from individual clinical trials.
Assessment of heterogeneity
We assessed heterogeneity among studies by using the Chi² test.
We quantified inconsistency by calculating I² and interpreted it
using the following guide (Higgins 2011).
• 0% to 40%: might not be important.
• 30% to 60%: may represent moderate heterogeneity.
• 50% to 90%: may represent substantial heterogeneity.
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
We planned to use the Egger’s regression intercept to assess report-
ing bias in our review. We planned to construct funnel plots and
evaluate their symmetry to visually assess publication bias, as long
as a sufficient number of trials (more than 10) were available.
Data synthesis
Weused ReviewManager 5.3 software for data synthesis (RevMan
2014). The first review author (Shahab H) entered extracted data
into Review Manager, and the second review author (Shahin H)
independently checked the data. We used random-effects or fixed-
effect modelling, as appropriate, for analysis. We applied random-
effects models if we identified considerable heterogeneity among
studies, as defined byHiggins 2011.We reported results in a forest
plot with 95% confidence intervals (CIs).
Subgroup analysis and investigation of heterogeneity
If possible, we planned to perform separate analyses for the fol-
lowing subgroups.
• Surgical patients.
• Trauma patients.
• ICU patients.
• Patients with chronic venous disease.
• Patients with neurological disorders.
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If possible, we planned to perform separate analyses for individual
NMES devices, old NMES devices (those no longer available for
use at present), and contemporary NMES devices.
Sensitivity analysis
To explore potential sources of heterogeneity and to assess the ro-
bustness of our results, we performed additional analyses for out-
comes reported by at least four studies. These included repeating
the primary analysis using random-effects and fixed-effect models,
calculating the pooled risk ratio (RR) or risk difference (RD) for
each dichotomous variable, and assessing the effect of each study
on overall effect size and heterogeneity by repeating the analysis
after removing one study at a time. We also performed sensitivity
analyses that excluded studies at high risk of bias.
’Summary of findings’ table
We constructed a table to compile and summarise the best evi-
dence on relevant outcomes of comparisons of NMES versus other
methods of thromboprophylaxis. We considered study popula-
tions consisting of patients with surgical, trauma, or medical con-
ditions. We selected the most important and clinically relevant
outcomes (both desirable and undesirable) thought to be essential
for decision-making for inclusion in the ’Summary of findings’
table. We have described these in the Types of outcome measures
section.We calculated assumed control intervention risks by using
the mean number of events in control groups of selected studies
for each outcome. We used the system developed by the Grad-
ing of Recommendation, Assessment, Development and Evalua-
tion Working Group (GRADE Working Group) in grading the
quality of evidence as high, moderate, low, and very low, based
on within-study risk of bias, directness of evidence, heterogeneity,
precision of effects estimates, and risk of publication bias (Atkins
2004; GRADEproGDT).
R E S U L T S
Description of studies
We have provided characteristics of the included studies in the
Characteristics of included studies section.
Results of the search
See Figure 1.
9Neuromuscular electrical stimulation for the prevention of venous thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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Included studies
We included five RCTs - Hou 2013; Kiudelis 2002; Lindstrom
1982; Merli 1988; Velmahos 2005 - and three quasi-randomised
trials - Bostrom 1986; Goyal 2012; Rosenberg 1975 - enrolling a
total of 904 participants. Among these, four studies included pa-
tients undergoing major surgical procedures (Hou 2013; Kiudelis
2002, Lindstrom 1982; Rosenberg 1975); one included patients
undergoing surgery for hip fracture under spinal anaesthesia
(Goyal 2012); one included trauma patients with a contraindi-
cation for prophylactic heparin (Velmahos 2005); one included
neurosurgical patients who were operated on under general anaes-
thesia (Bostrom 1986); and one included patients with non-func-
tional spinal cord injuries (Merli 1988).We have reported in Table
1 the NMES delivery settings used in the included studies.
Four studies comparedNMES versus no prophylaxis (Goyal 2012;
Hou 2013; Lindstrom 1982; Rosenberg 1975). Two studies com-
pared NMES versus low-dose heparin (5000 IU subcutaneously)
(Bostrom 1986; Rosenberg 1975). One study compared NMES
versusDextran40 (Lindstrom 1982).One study comparedNMES
with no prophylaxis or with low-dose heparin (Velmahos 2005).
One study compared combined NMES and low-dose heparin ver-
sus no prophylaxis or low-dose heparin alone (Merli 1988). One
study compared NMES versus GCS and IPCD (Kiudelis 2002).
Six studies deliveredNMES perioperatively (Bostrom1986;Goyal
2012; Hou 2013; Kiudelis 2002; Lindstrom 1982; Rosenberg
1975).
In terms of methods to diagnose DVT, two studies used duplex
ultrasonography (Goyal 2012; Hou 2013); one used either du-
plex ultrasonography or venography (Velmahos 2005); four used
the fibrinogen uptake test with or without venography (Bostrom
1986; Lindstrom 1982; Merli 1988; Rosenberg 1975); and one
used venous occlusion plethysmography (Kiudelis 2002). Theme-
dian duration of follow-up in the included studies was seven days
(Interquartile range: five).
Excluded studies
We excluded 17 studies from the review (Browse 1970; Czyrny
2010; Doran 1967; Doran 1970; Faghri 1998; Hou 2014; Izumi
2014; Jansen 1972; Kaplan 2002; Lobastov 2014; Morita 2006;
NCT02425917; Nicolaides 1983; Ojima 2017; Pambianco 1995;
Rosengarten 1975; Yilmaz 2016). Among these, we excluded three
studies because they included healthy participants (Czyrny 2010;
Kaplan 2002;Morita 2006); four studies because they randomised
legs instead of participants (Browse 1970; Doran 1967; Doran
1970; Nicolaides 1983); two studies because they were non-ran-
domised studies (Faghri 1998; Lobastov 2014); two studies be-
cause they investigated non-mechanical methods of prophylaxis
only (Jansen 1972;Rosengarten 1975); one study because only one
leg was treated with NMES (Izumi 2014); one study because the
NMES arm was terminated early in the pilot phase (Pambianco
1995); one study because researchers did not report the outcomes
specified in this review (Hou 2014); two studies because they in-
vestigated haemodynamic outcomes and were powered for these
outcomes only (Ojima 2017; Yilmaz 2016); and one study because
the trial had been withdrawn before enrolment (NCT02425917).
Moreover, we assessed three articles containing data about unpub-
lished trials for potentially eligible trials, but we identified no el-
igible trials, as all trials included healthy participants (Firstkind
2013; NICE 2011; Summers 2015).
In addition, we identified two relevant ongoing trials, results
of which were not available at the time of this writing (
ISRCTN95441725; NCT01935414). One study is still awaiting
classification because the study has been completed but study re-
sults are not yet available (NCT01835990).
Risk of bias in included studies
We have presented the summary and results of methodological
quality assessment graphically in Figure 2 and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
In terms of random sequence generation, we judged one study
to be at low risk of selection bias (Hou 2013); three studies to
be at high risk of selection bias because of inappropriate method
of randomisation (Bostrom 1986; Goyal 2012; Rosenberg 1975);
and four studies to be at unclear risk of selection bias because
they did not report information about methods of randomisation
(Kiudelis 2002; Lindstrom 1982; Merli 1988; Velmahos 2005).
In terms of allocation concealment, we judged three studies to
be at high risk of bias (Bostrom 1986; Goyal 2012; Rosenberg
1975). The remaining studies did not provide adequate informa-
tion about allocation concealment; therefore, risk of bias is un-
clear in these studies (Hou 2013; Kiudelis 2002; Lindstrom 1982;
Merli 1988; Velmahos 2005).
Blinding
We judged risk of performance bias to be low in one study (Merli
1988). We judged risk of performance bias to be high in seven
studies because trialists performed no blinding of participants and
personnel (Bostrom 1986;Goyal 2012;Hou 2013; Kiudelis 2002;
Lindstrom 1982; Rosenberg 1975; Velmahos 2005).
We judged risk of detection bias to be low in Goyal 2012 and
high in Bostrom 1986. We were not able to assess risk of detection
bias in the other studies, as reporting about blinding of outcome
assessment was insufficient (Hou 2013; Kiudelis 2002; Lindstrom
1982; Merli 1988; Rosenberg 1975; Velmahos 2005).
Incomplete outcome data
We judged seven studies to be at low risk of attrition bias (Bostrom
1986; Goyal 2012; Hou 2013; Kiudelis 2002; Lindstrom 1982;
Merli 1988; Rosenberg 1975). We judged risk of attrition bias to
be high in one study because missing data were not balanced in
numbers across intervention groups (Velmahos 2005).
Selective reporting
We judged risk of reporting bias in all included studies as low
because although the protocols of the included studies were not
available, it is clear that published reports included all expected
outcomes.
Other potential sources of bias
We judged three studies to be potentially at high risk of bias be-
cause they were Industry sponsored (Hou 2013; Rosenberg 1975;
Velmahos 2005). We deemed the remaining five studies to be at
low risk of bias, as we identified no other potential sources of
bias (Bostrom 1986;Goyal 2012; Kiudelis 2002; Lindstrom 1982;
Merli 1988).
Effects of interventions
See: Summary of findings for the main comparison NMES
compared to alternative prophylaxis for the prevention of venous
thromboembolism; Summary of findings 2 NMES compared
to no prophylaxis for prevention of venous thromboembolism;
Summary of findings 3 NMES compared to low-dose heparin
for the prevention of venous thromboembolism; Summary of
findings 4NMES compared to Dextran 40 for the prevention of
venous thromboembolism; Summary of findings 5 Combined
NMES and low-dose heparin compared to no prophylaxis for the
prevention of venous thromboembolism; Summary of findings
6 Combined NMES and low-dose heparin compared to low-
dose heparin for the prevention of venous thromboembolism;
Summary of findings 7 NMES compared to GCS for the
prevention of venous thromboembolism; Summary of findings
8 NMES compared to IPCD for the prevention of venous
thromboembolism
Available data allowed us to perform eight comparisons. We have
presented details about these comparisons in theData and analyses
section. In brief, we present data comparing NMES versus no pro-
phylaxis, NMES versus alternative prophylaxis that is combining
all studies using an alternative prophylaxis as a comparator, and
NMES versus individual comparisons making up the alternative
prophylaxis.
NMES versus alternative prophylaxis
This comparison includes all studies comparing NMES (alone or
in combination with other methods of prophylaxis) versus any
other method of VTE prophylaxis (Bostrom 1986; Kiudelis 2002;
Lindstrom 1982; Merli 1988; Rosenberg 1975; Velmahos 2005).
Total DVT
Six studies, enrolling a total of 415 participants, reported total
DVT (Bostrom 1986; Kiudelis 2002; Lindstrom 1982; Merli
1988;Rosenberg 1975;Velmahos 2005).Data shownodifferences
in risk of total DVT between NMES and alternative prophylaxis
groups (odds ratio (OR) 1.01, 95% confidence interval (CI) 0.60
to 1.70, P = 0.98; low-quality evidence). Studies show a moderate
level of heterogeneity (I2 = 62%, P = 0.02) (Analysis 1.1) (Figure
4).
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Figure 4. Forest plot of comparison: 1 NMES versus alternative prophylaxis, outcome: 1.1 Total DVT.
Asymptomatic DVT
One study, enrolling a total of 89 participants, reported asymp-
tomatic DVT (Bostrom 1986). Data show no clear differences in
the risk of asymptomatic DVT between NMES and alternative
prophylaxis groups (OR 1.61, 95% CI 0.40 to 6.43, P = 0.50;
low-quality evidence) (Analysis 1.2).
Symptomatic DVT
One study, enrolling a total of 89 participants, reported symp-
tomatic DVT (Bostrom 1986). Data show no clear differences
in the risk of symptomatic DVT between NMES and alternative
prophylaxis groups (OR 0.40, 95% CI 0.02 to 10.07, P = 0.58;
low-quality evidence) (Analysis 1.3).
PE
Two studies, enrolling a total of 126 participants, reported PE (
Kiudelis 2002; Lindstrom 1982).Data showno clear differences in
the risk of PE between NMES and alternative prophylaxis groups
(OR 1.31, 95% CI 0.38 to 4.48, P = 0.67; low-quality evidence).
Studies show a low level of heterogeneity (I2 = 0%, P = 0.64)
(Analysis 1.4).
Total VTE
One study, enrolling a total of 72 participants, reported total VTE
(Lindstrom 1982). Data show no clear differences in the risk of
total VTEbetweenNMES and alternative prophylaxis groups (OR
0.92, 95% CI 0.34 to 2.52, P = 0.88; low-quality evidence) (
Analysis 1.5).
The included studies did not report the other primary and sec-
ondary outcome measures of this review for this comparison.
NMES versus no prophylaxis
Total DVT
Four studies, enrolling a total of 576 participants, reported to-
tal DVT (Goyal 2012; Hou 2013; Lindstrom 1982; Rosenberg
1975). Prophylaxis with NMES was associated with lower risk of
DVT than no prophylaxis (OR 0.40, 95% CI 0.23 to 0.70, P
= 0.001; moderate-quality evidence). Studies show a low level of
heterogeneity (I2 = 0%, P = 0.61) (Analysis 2.1) (Figure 5).
Figure 5. Forest plot of comparison: 2 NMES versus no prophylaxis, outcome: 2.1 Total DVT.
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Asymptomatic DVT
One study, enrolling a total of 200 participants, reported asymp-
tomatic DVT (Goyal 2012). Data show no clear differences in the
risk of asymptomatic DVT between NMES and no prophylaxis
groups (OR 0.32, 95% CI 0.06 to 1.62, P = 0.17; low-quality
evidence) (Analysis 2.2).
Symptomatic DVT
One study, enrolling a total of 160 participants, reported symp-
tomatic DVT (Hou 2013). Data show no clear differences in the
risk of symptomatic DVT between NMES and no prophylaxis
groups (OR 0.06, 95% CI 0.00 to 1.36, P = 0.08; low-quality
evidence) (Analysis 2.3).
PE
One study, enrolling a total of 77 participants, reported PE
(Lindstrom 1982). Data show no clear differences in the risk of
PE between NMES and no prophylaxis groups (OR 0.36, 95%
CI 0.12 to 1.07, P = 0.07; low-quality evidence) (Analysis 2.4).
Total VTE
One study, enrolling a total of 77 participants, reported total VTE
(Lindstrom 1982). Risk of total VTE was lower in the NMES
group than in the no prophylaxis group (OR 0.23, 95% CI 0.09
to 0.59, P = 0.002; low-quality evidence) (Analysis 2.5).
The included studies did not report the other primary and sec-
ondary outcome measures of this review for this comparison.
NMES versus low-dose heparin
Total DVT
Two studies, enrolling a total of 194 participants, reported total
DVT (Bostrom 1986; Rosenberg 1975). Prophylaxis with NMES
was associated with higher risk of DVT than prophylaxis with
low-dose heparin (OR 2.78, 95% CI 1.19 to 6.48, P = 0.02; low-
quality evidence). Studies show a moderate level of heterogeneity
(I2 = 57%, P = 0.13) (Analysis 3.1).
Asymptomatic DVT
One study, enrolling a total of 89 participants, reported asymp-
tomatic DVT (Bostrom 1986). Data show no clear differences
in the risk of asymptomatic DVT between NMES and low-dose
heparin groups (OR 1.61, 95% CI 0.40 to 6.43, P = 0.50; low-
quality evidence) (Analysis 3.2).
Symptomatic DVT
One study, enrolling a total of 89 participants, reported symp-
tomatic DVT (Bostrom 1986). Data show no clear differences
in the risk of symptomatic DVT between NMES and low-dose
heparin groups (OR 0.40, 95% CI 0.02 to 10.07, P = 0.58; low-
quality evidence) (Analysis 3.3).
The included studies did not report the other primary and sec-
ondary outcome measures of this review for this comparison.
NMES versus Dextran 40
Total DVT
One study, enrolling a total of 72 participants, reported total DVT
(Lindstrom 1982). Data show no clear differences in the risk of
DVT between NMES and Dextran 40 groups (OR 0.63, 95% CI
0.18 to 2.19, P = 0.46; low-quality evidence) (Analysis 4.1).
PE
One study, enrolling a total of 72 participants, reported PE
(Lindstrom 1982). Data show no clear differences in the risk of
PE between NMES and Dextran 40 groups (OR 1.50, 95% CI
0.39 to 5.84, P = 0.56; low-quality evidence) (Analysis 4.2).
Total VTE
One study, enrolling a total of 72 participants, reported total VTE
(Lindstrom 1982). Data show no clear differences in the risk of
total VTE between NMES and Dextran 40 groups (OR 0.92,
95% CI 0.34 to 2.52, P = 0.88; low-quality evidence) (Analysis
4.3).
The included studies did not report the other primary and sec-
ondary outcome measures of this review for this comparison.
Combined NMES and low-dose heparin versus no
prophylaxis
Total DVT
One study, enrolling a total of 32 participants, reported total DVT
(Merli 1988).NMES combined with low-dose heparin was associ-
ated with lower risk of DVT when compared with no prophylaxis
(OR 0.08, 95% CI 0.01 to 0.76, P = 0.03; low-quality evidence)
(Analysis 5.1).
The included studies did not report the other primary and sec-
ondary outcome measures of this review for this comparison.
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Combined NMES and low-dose heparin versus low-
dose heparin
Total DVT
One study, enrolling a total of 31 participants, reported total DVT
(Merli 1988). NMES combined with low-dose heparin was as-
sociated with lower risk of DVT when compared with low-dose
heparin alone (OR 0.07, 95% CI 0.01 to 0.68, P = 0.02; low-
quality evidence) (Analysis 6.1).
The included studies did not report the other primary and sec-
ondary outcome measures of this review for this comparison.
NMES versus GCS
Total DVT
One study, enrolling a total of 36 participants, reported total DVT
(Kiudelis 2002). Data show no clear differences in the risk of DVT
betweenNMES andGCS groups (OR 0.32, 95%CI 0.01 to 8.27,
P = 0.49; low-quality evidence) (Analysis 7.1).
PE
One study, enrolling a total of 36 participants, reported PE
(Kiudelis 2002). Data show no clear differences in the risk of PE
betweenNMES andGCS groups (OR 0.32, 95%CI 0.01 to 8.27,
P = 0.49; low-quality evidence) (Analysis 7.2).
The included studies did not report the other primary and sec-
ondary outcome measures of this review for this comparison.
NMES versus IPCD
Total DVT
One study, enrolling a total of 36 participants, reported total DVT
(Kiudelis 2002). Owing to the occurrence of no DVT in either
group, the OR was not estimable (Analysis 8.1).
PE
One study, enrolling a total of 36 participants, reported PE
(Kiudelis 2002).Owing to the occurrence of noPE in either group,
the OR was not estimable (Analysis 8.2).
The included studies did not report the other primary and sec-
ondary outcome measures of this review for this comparison.
Subgroup analysis
We planned to perform subgroup analyses for surgical patients,
trauma patients, ICU patients, patients with chronic venous dis-
ease, and patients with neurological disorders. However, after con-
sidering the limited number of studies, the quality of available
data, the heterogeneity of included populations, NMES delivery
systems, and the duration and frequency of stimulation, we de-
cided not to perform any subgroup analyses in this review.
Available data did not allow for separate analyses based on individ-
ual NMES devices, old NMES devices (those no longer available
for use at present), and contemporary NMES devices.
Sensitivity analysis
After considering the limited number of included studies, we per-
formed sensitivity analysis for only one outcome measure in two
comparisons (i.e. comparisons for which more than four studies
reported the outcome) (Analysis 1.1; Analysis 2.1).
Total DVT in NMES versus alternative prophylaxis
comparison
Use of random-effects or fixed-effect models did not affect the
direction of the effect size (Analysis 1.1). Moreover, the direction
of the effect size remained unchanged when pooled RRs or RDs
were calculated. Removing one study at a time did not change
the direction of the effect size and overall heterogeneity in this
analysis. Excluding studies judged to be at high risk of bias did
not change the direction of the effect size.
Total DVT in NMES versus no prophylaxis comparison
Use of random-effects or fixed-effect models did not affect the
direction of the effect size (Analysis 2.1). Moreover, the direction
of the effect size remained unchanged when pooled RRs or RDs
were calculated. Removing one study at a time did not change
the direction of the effect size and overall heterogeneity in this
analysis. Excluding studies judged to be at high risk of bias did
not change the direction of the effect size.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
NMES compared to no prophylaxis for prevent ion of venous thromboembolism
Patient or population: part icipants at risk of venous thromboembolism
Setting: hospital, secondary care
Intervention: NMES
Comparison: no prophylaxis
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no prophy-
laxis
Risk with NMES
Total DVT
Follow-up: mean 7 days
Study populat ion OR 0.40
(0.23 to 0.70)
576
(4 RCTs)
⊕⊕⊕©
MODERATEa
219 per 1000 101 per 1000
(61 to 164)
Asymptomatic DVT
Follow-up: 7 days
Study populat ion OR 0.32
(0.06 to 1.62)
200
(1 RCT)
⊕⊕©©
LOWa,b
60 per 1000 20 per 1000
(4 to 94)
Symptomatic DVT
Follow-up: 7 days
Study populat ion OR 0.06
(0.00 to 1.36)
160
(1 RCT)
⊕⊕©©
LOWa,b
50 per 1000 3 per 1000
(0 to 67)
PE
Follow-up: 6 days
Study populat ion OR 0.36
(0.12 to 1.07)
77
(1 RCT)
⊕⊕©©
LOWa,b
350 per 1000 162 per 1000
(61 to 366)
Total VTE
Follow-up: 6 days
Study populat ion OR 0.23
(0.09 to 0.59)
77
(1 RCT)
⊕⊕©©
LOWa,b
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650 per 1000 299 per 1000
(143 to 523)
Bleeding (major and mi-
nor)
see comment see comment not est imable 576
(4 RCTs)
- None of the studies
in this comparison re-
ported this outcome
*Assumed control intervent ion risks were calculated by the mean number of events in control groups of selected studies for each outcome. The risk in the intervention group
(and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; NMES: neuromuscular electrical st imulat ion; OR: odds rat io; PE: pulmonary embolism; RCT: randomised controlled trial;
VTE: venous thromboembolism
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aHigh or unclear risk of select ion bias, performance bias, and detect ion bias - downgraded by one level.
bFew part icipants and few events and thus wide conf idence intervals - downgraded by one level.
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NMES compared to low-dose heparin for the prevent ion of venous thromboembolism
Patient or population: part icipants at risk of venous thromboembolism
Setting: hospital, secondary care
Intervention: NMES
Comparison: low-dose heparin
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with low-dose
heparin
Risk with NMES
Total DVT
Follow-up: mean 7 days
Study populat ion OR 2.78
(1.19 to 6.48)
194
(2 RCTs)
⊕⊕©©
LOWa,b
87 per 1000 208 per 1000
(101 to 380)
Asymptomatic DVT
Follow-up: 8 days
Study populat ion OR 1.61
(0.40 to 6.43)
89
(1 RCT)
⊕⊕©©
LOWb,c
82 per 1000 125 per 1000
(34 to 364)
Symptomatic DVT
Follow-up: 8 days
Study populat ion OR 0.40
(0.02 to 10.07)
89
(1 RCT)
⊕⊕©©
LOWb,c
20 per 1000 8 per 1000
(0 to 173)
PE see comment see comment not est imable 194
(2 RCTs)
- None of the studies
in this comparison re-
ported this outcome
Total VTE see comment see comment not est imable 194
(2 RCTs)
- None of the studies
in this comparison re-
ported this outcome
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Bleeding (major and mi-
nor)
see comment see comment not est imable 194
(2 RCTs)
- None of the studies
in this comparison re-
ported this outcome
*Assumed control intervent ion risks were calculated by the mean number of events in control groups of selected studies for each outcome. The risk in the intervention group
(and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; NMES: neuromuscular electrical st imulat ion; OR: odds rat io; PE: pulmonary embolism; RCT: randomised controlled trial;
VTE: venous thromboembolism
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aHigh or unclear risk of select ion bias, performance bias, and detect ion bias - downgraded by one level.
bFew part icipants and few events and thus wide conf idence intervals - downgraded by one level.
cHigh or unclear risk of select ion bias and detect ion bias - downgraded by one level.
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NMES compared to Dextran 40 for the prevent ion of venous thromboembolism
Patient or population: part icipants at risk of venous thromboembolism
Setting: hospital, secondary care
Intervention: NMES
Comparison: Dextran 40
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with Dextran 40 Risk with NMES
Total DVT
Follow-up: 6 days
Study populat ion OR 0.63
(0.18 to 2.19)
72
(1 RCT)
⊕⊕©©
LOWa,b
200 per 1000 136 per 1000
(43 to 354)
Asymptomatic DVT see comment see comment not est imable 72
(1 RCT)
- The single study in this
comparison did not re-
port this outcome
Symptomatic DVT see comment see comment not est imable 72
(1 RCT)
- The single study in this
comparison did not re-
port this outcome
PE
Follow-up: 6 days
Study populat ion OR 1.50
(0.39 to 5.84)
72
(1 RCT)
⊕⊕©©
LOWa,b
114 per 1000 162 per 1000
(48 to 430)
Total VTE
Follow-up: 6 days
Study populat ion OR 0.92
(0.34 to 2.52)
72
(1 RCT)
⊕⊕©©
LOWa,b
314 per 1000 297 per 1000
(135 to 536)
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Bleeding (major and mi-
nor)
see comment see comment not est imable 72
(1 RCT)
- The single study in this
comparison did not re-
port this outcome
Assumed control intervent ion risks were calculated by the mean number of events in control groups of selected studies for each outcome. * The risk in the intervention group
(and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; NMES: neuromuscular electrical st imulat ion; OR: odds rat io; PE: pulmonary embolism; RCT: randomised controlled trial;
VTE: venous thromboembolism
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect,
aHigh or unclear risk of select ion bias, performance bias, and detect ion bias - downgraded by one level.
bSingle study, few part icipants, and few events and thus wide conf idence intervals - downgraded by one level.
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Combined NMES and low-dose heparin compared to no prophylaxis for the prevent ion of venous thromboembolism
Patient or population: part icipants at risk of venous thromboembolism
Setting: hospital, secondary care
Intervention: combined NMES and low-dose heparin
Comparison: no prophylaxis
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no prophy-
laxis
Risk with combined
NMES and low-dose
heparin
Total DVT
Follow-up: 28 days
Study populat ion OR 0.08
(0.01 to 0.76)
32
(1 RCT)
⊕⊕©©
LOWa,b
471 per 1000 66 per 1000
(9 to 403)
Asymptomatic DVT see comment see comment not est imable 32
(1 RCT)
- The single study in this
comparison did not re-
port this outcome
Symptomatic DVT see comment see comment not est imable 32
(1 RCT)
- The single study in this
comparison did not re-
port this outcome
PE see comment see comment not est imable 32
(1 RCT)
- The single study in this
comparison did not re-
port this outcome
Total VTE see comment see comment not est imable 32
(1 RCT)
- The single study in this
comparison did not re-
port this outcome
2
4
N
e
u
ro
m
u
sc
u
la
r
e
le
c
tric
a
l
stim
u
la
tio
n
fo
r
th
e
p
re
v
e
n
tio
n
o
f
v
e
n
o
u
s
th
ro
m
b
o
e
m
b
o
lism
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Bleeding (major and mi-
nor)
see comment see comment not est imable 32
(1 RCT)
- The single study in this
comparison did not re-
port this outcome
*Assumed control intervent ion risks were calculated by the mean number of events in control groups of selected studies for each outcome. The risk in the intervention group
(and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; NMES: neuromuscular electrical st imulat ion; OR: odds rat io; PE: pulmonary embolism; RCT: randomised controlled trial;
VTE: venous thromboembolism
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aHigh or unclear risk of select ion bias and detect ion bias - downgraded by one level.
bSingle study, few part icipants, and few events and thus wide conf idence intervals - downgraded by one level.
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Combined NMES and low-dose heparin compared to low-dose heparin for the prevent ion of venous thromboembolism
Patient or population: part icipants at risk of venous thromboembolism
Setting: hospital, secondary care
Intervention: combined NMES and low-dose heparin
Comparison: low-dose heparin
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with low-dose
heparin
Risk with combined
NMES and low-dose
heparin
Total DVT
Follow-up: 28 days
Study populat ion OR 0.07
(0.01 to 0.68)
31
(1 RCT)
⊕⊕©©
LOWa,b
500 per 1000 65 per 1000
(10 to 405)
Asymptomatic DVT see comment see comment not est imable 31
(1 RCT)
- The single study in this
comparison did not re-
port this outcome
Symptomatic DVT see comment see comment not est imable 31
(1 RCT)
- The single study in this
comparison did not re-
port this outcome
PE see comment see comment not est imable 31
(1 RCT)
- The single study in this
comparison did not re-
port this outcome
Total VTE see comment see comment not est imable 31
(1 RCT)
- The single study in this
comparison did not re-
port this outcome
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Bleeding (major and mi-
nor)
see comment see comment not est imable 31
(1 RCT)
- The single study in this
comparison did not re-
port this outcome
*Assumed control intervent ion risks were calculated by the mean number of events in control groups of selected studies for each outcome. The risk in the intervention group
(and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; NMES: neuromuscular electrical st imulat ion; OR: odds rat io; PE: pulmonary embolism; RCT: randomised controlled trial;
VTE: venous thromboembolism
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aHigh or unclear risk of select ion bias and detect ion bias - downgraded by one level.
bSingle study, few part icipants, and few events and thus wide conf idence intervals - downgraded by one level.
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NMES compared to GCS for the prevent ion of venous thromboembolism
Patient or population: part icipants at risk of venous thromboembolism
Setting: hospital, secondary care
Intervention: NMES
Comparison: GCS
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with GCS Risk with NMES
Total DVT
Follow-up: 1 day
Study populat ion OR 0.32
(0.01 to 8.27)
36
(1 RCT)
⊕⊕©©
LOWa,b
56 per 1000 18 per 1000
(1 to 327)
Asymptomatic DVT see comment see comment not est imable 36
(1 RCT)
- None of the studies
in this comparison re-
ported this outcome
Symptomatic DVT see comment see comment not est imable 36
(1 RCT)
- None of the studies
in this comparison re-
ported this outcome
PE
Follow-up: 1 day
Study populat ion OR 0.32
(0.01 to 8.27)
36
(1 RCT)
⊕⊕©©
LOWa,b
56 per 1000 18 per 1000
(1 to 327)
Total VTE see comment see comment not est imable 36
(1 RCT)
- None of the studies
in this comparison re-
ported this outcome
Bleeding (major and mi-
nor)
see comment see comment not est imable 36
(1 RCT)
- None of the studies
in this comparison re-
ported this outcome28
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* Assumed control intervent ion risks were calculated by the mean number of events in control groups of selected studies for each outcome. The risk in the intervention group
(and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; GCS: graduated compression stockings; NMES: neuromuscular electrical st imulat ion; OR: odds rat io; PE: pulmonary
embolism; RCT: randomised controlled trial; VTE: venous thromboembolism
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aHigh or unclear risk of select ion bias, performance bias, and detect ion bias - downgraded by one level.
bSingle study, few part icipants, and few events and thus wide conf idence intervals - downgraded by one level.
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NMES compared to IPCD for the prevent ion of venous thromboembolism
Patient or population: part icipants at risk of venous thromboembolism
Setting: hospital, secondary care
Intervention: NMES
Comparison: IPCD
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with IPCD Risk with NMES
Total DVT
Follow-up: 1 day
Study populat ion not est imable 36
(1 RCT)
⊕⊕©©
LOWa,b
No DVT events were
recorded.
see comment see comment
Asymptomatic DVT see comment see comment not est imable 36
(1 RCT)
- None of the studies in this
comparison reported this
outcome
Symptomatic DVT see comment see comment not est imable 36
(1 RCT)
- None of the studies in this
comparison reported this
outcome
PE
Follow-up: 1 day
Study populat ion not est imable 36
(1 RCT)
⊕⊕©©
LOWa,b
No PE events were
recorded.
see comment see comment
Total VTE see comment see comment not est imable 36
(1 RCT)
- None of the studies in this
comparison reported this
outcome
Bleeding (major and mi-
nor)
see comment see comment not est imable 36
(1 RCT)
- None of the studies in this
comparison reported this
outcome
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* Assumed control intervent ion risks were calculated by the mean number of events in control groups of selected studies for each outcome. The risk in the intervention group
(and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; IPCD: interm it tent pneumatic compression devices; NMES: neuromuscular electrical st imulat ion; OR: odds rat io; PE:
pulmonary embolism; RCT: randomised controlled trial; VTE: venous thromboembolism
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aHigh or unclear risk of select ion bias, performance bias, and detect ion bias - downgraded by one level.
bSingle study, few part icipants, and few events - downgraded by one level.
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D I S C U S S I O N
Summary of main results
We conducted a systematic review of randomised controlled tri-
als and quasi-randomised trials of reported outcomes to evaluate
the effectiveness of neuromuscular electrical stimulation systems
(NMES) in the prevention of venous thromboembolism (VTE).
We included eight trials, enrolling a total of 904 participants. Our
results show no differences in the risk of deep vein thrombosis
(DVT) between NMES and alternative methods of prophylaxis
(odds ratio (OR) 1.01, 95% confidence interval (CI) 0.60 to 1.70,
P = 0.98; low-quality evidence; 6 studies, 415 participants). Our
analysis also shows that prophylaxis with NMES was associated
with lower risk of DVT compared with no prophylaxis (OR 0.40,
95%CI 0.23 to 0.70, P = 0.02; moderate-quality evidence; 4 stud-
ies, 576participants); however, prophylaxiswithNMESwas found
to be associated with higher risk of DVT than prophylaxis with
low-dose heparin (OR 2.78, 95% CI 1.19 to 6.48, P = 0.02; low-
quality evidence; 2 studies, 194 participants). Available evidence
did not allow us to reach a conclusion regarding the effectiveness
of NMES in comparison with other mechanical or pharmacolog-
ical methods of prophylaxis owing to limited data. The effect of
NMES on some clinical outcomes such as symptomatic or asymp-
tomatic DVT, pulmonary embolism (PE), total VTE, bleeding, or
patient compliance remains unknown. The included studies were
considerably heterogeneous in terms of participant populations
and settings; devices and settings used to deliver NMES; duration
and frequency of electrical stimulation; and methods used to di-
agnose VTE.
Overall completeness and applicability of
evidence
The best available evidence about the effectiveness of NMES in
the prevention of VTE is not adequately robust to allow defini-
tive conclusions. Available evidence shows that NMESwhen com-
pared with no prophylaxis was associated with lower risk of DVT;
this suggests that NMES may be beneficial for individuals who
are at high risk for VTE and are unable to receive any other me-
chanical or pharmacologicalmethods of prophylaxis.However, the
available evidence is derived from a very small number of studies
with generally small sample sizes. We found inadequate evidence
on the effectiveness of NMES versus commonly used mechanical
methods of prophylaxis such as graduated compression stockings
(GCS) and intermittent pneumatic compression devices (IPCD),
which have been shown to be effective in VTE prophylaxis (Pavon
2016; Sachdeva 2014). Available evidence about effects of NMES
on clinical VTE outcomes compared with pharmacological meth-
ods of prophylaxis is inconclusive. Moreover, the additional effec-
tiveness of NMES combined with other methods of VTE prophy-
laxis remains unknown.
Bleeding was one of the primary outcomes of the current review
that was not reported by any of the included trials.Moreover, none
of the included trials reported physiological measurements or free-
dom from VTE at 90 days as an outcome. Poor patient compli-
ance is one of the principal disadvantages of mechanical meth-
ods of prophylaxis. None of the included studies reported patient
compliance or NMES device-related adverse effects; therefore, it
remains unclear whetherNMESwould result in better compliance
in comparison with other methods of mechanical prophylaxis.
Heterogeneity among the included studies did not allow us to
define the most effective device and setting for delivery of NMES.
Moreover, evidence is insufficient to allow defining a group of
patients who can benefit most from NMES as a method of VTE
prophylaxis.
Quality of the evidence
See Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5; Summary of findings 6; Summary of
findings 7; and Summary of findings 8.
Overall, the quality of available evidence is low.
Allocation concealment and blinding of participants were inade-
quate in most of the included trials, subjecting them to high risk of
selection and performance bias, respectively. Moreover, included
studies show poorly reported blinding of outcome assessment, in-
creasing the likelihood of detection bias. Consequently, the poor
reporting and methodological quality of the included trials did
not allow us to synthesise robust evidence about the effectiveness
of NMES in the prevention of VTE.
For each comparison, a very limited number of studies reported
most of the outcomes; therefore, few participants and few events
may have led to imprecise effect estimates, reflected by wide confi-
dence intervals for calculatedORs.Moreover, the included studies
were heterogeneous in terms of participant populations and set-
tings for delivery of NMES.
Most of the included studies did not contribute to one or more of
the primary and secondary outcomes of our review (e.g. bleeding,
device-related adverse effects), subjecting the available evidence to
some publication bias.
Potential biases in the review process
Tominimise the risk of bias in this review, at least two independent
review authors were involved in study selection, data extraction,
methodological quality assessment, and data analysis. Some bias
in the review process may arise, as the results of two ongoing trials
were not available; we will include these trials in future updates of
this review (ISRCTN95441725; NCT01935414).
Agreements and disagreements with other
studies or reviews
In a recent systematic review of 21 randomised and non-ran-
domised studies, we identified conflicting evidence on the effect of
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NMES on the incidence of VTE (Hajibandeh 2015). Moreover,
among the studies that compared the incidence of DVT in stim-
ulated versus non-stimulated legs in the same participant, some
reported a reduction in the incidence of DVT in the stimulated
leg (Browse 1970; Doran 1967; Nicolaides 2013), whereas oth-
ers found no difference in the risk of DVT between legs (Doran
1970). NMES has proved experimentally effective in increasing
venous blood velocity and flow; however, controversy exists as to
whether venous velocity and flow should be used as surrogate out-
come measures for the risk of VTE (Hajibandeh 2015). NMES
may prevent VTE via other mechanisms. It has been argued that
neuromuscular stimulation of the veins provides direct antithrom-
botic effects as a fourth factor not included in Virchow’s triad;
NMES, via neurogenic pathways, may influence this fourth factor
and suppress thrombogenesis (Stefanou 2016). This highlights the
need for additional studies on themechanisms of VTEprevention.
Although available clinical trials have not reported any outcomes
regarding tolerability of NMES, evidence from experimental stud-
ies suggests that modern NMES devices appear to be associated
with mild pain and discomfort that can potentially lead to good
patient compliance (Broderick 2010; Broderick 2013; Moloney
2006; Warwick 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Low-quality evidence suggests no clear differences in the risk of
deep vein thrombosis (DVT) between neuromuscular electrical
stimulation systems (NMES) and alternative methods of prophy-
laxis, but moderate-quality evidence shows that NMES was asso-
ciated with lower risk of DVT when compared with no prophy-
laxis, and low-quality evidence suggests higher risk of DVT when
compared with low-dose heparin. The best available evidence on
the effectiveness of NMES in the prevention of VTE is not ade-
quately robust to permit definitive conclusions.
Implications for research
Adequately powered high-quality randomised controlled trials are
required to provide robust evidence on:
• effectiveness of NMES versus other pharmacological or
mechanical methods of VTE prophylaxis;
• additional effects of NMES combined with other methods
on VTE prophylaxis;
• cost-effectiveness of NMES in the setting of VTE
prophylaxis;
• the most effective device and setting for delivery of NMES;
and
• the population that can potentially benefit most from
NMES as a method of prophylaxis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bostrom 1986
Methods Quasi-randomised case-controlled trial
Participants Number of participants: 104 (NMES: 46; low-dose heparin: 58)
Inclusion criteria: neurosurgical patients aged 40 years or older with normal laboratory
coagulation values and operated on under general anaesthesia
Interventions NMES group: preoperative calf muscle stimulation with groups of impulses, followed by
Dextran 70 administered postoperatively. Stimulation characteristics included stimulus
strength 40 to 50 mA; impulse duration 50ms; number of impulses per group 6; impulse
frequency within groups 8 per second; group frequency 8 per minute
Low-dose heparin group: Heparin (sodium heparin, Heparin, Lrvens, 5000 IU × 2
subcutaneously) was administered 2 hours preoperatively and was continued daily for 1
week postoperatively
Outcomes DVT (Participants were screened by fibrinogen uptake test; whenever possible, a phle-
bography was performed.)
Notes Of 122 participants who entered the study, 18 were excluded during the course of the
study. The most common reason for not completing the prophylaxis for the intended full
week was early discharge from the hospital. One participant died 5 days after clipping
of a ruptured intracranial aneurysm
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk The participant’s year of birth was chosen as a
method for randomisation
Allocation concealment (selection bias) High risk The study was quasi-randomised, and alloca-
tion was not adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants and personnel was
reported.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk US or CT operator/radiologist was not
blinded to patient allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of 122 participants who entered the study,
18 were excluded during the course of the
study. However, the missing outcome data
were balanced in numbers across intervention
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Bostrom 1986 (Continued)
groups, and reasons for missing data were sim-
ilar across groups
Selective reporting (reporting bias) Low risk The study protocol was not available, but it
is clear that published reports include all ex-
pected outcomes
Other bias Low risk None was identified.
Goyal 2012
Methods Quasi-randomised case-controlled trial
Participants Number of participants: 200 (NMES: 100; no prophylaxis: 100)
Inclusion criteria: patients > 25 years of age requiring surgery around the hip joint who
underwent surgery within 2 weeks of sustaining trauma and were operated on under
spinal anaesthesia
Exclusion criteria: established cases of DVT; taking antithrombotic medication; open
fractures; pacemakers; other serious life-threatening conditions, pathological fractures,
and associated vascular injuries
Interventions NMES group: VeinoPlus (Ad Rem Technology, Paris, France) stimulator device for
electrostimulation of the calf muscles during surgery. The stimulator device delivered
low-voltage (peak value usually around 15 to 25 V) and small-energy impulses (below
25 µC per impulse) to calf muscles
Control group: no prophylaxis
Outcomes DVT (diagnosed by Doppler ultrasound 7 days after surgery)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Participants were randomised into 2 groups of
100 participants each by odd-even number
Allocation concealment (selection bias) High risk The study was quasi-randomised, and alloca-
tion was not adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding was reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The radiologist was blinded about the study
and groups of participants
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Goyal 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No outcome data were missing.
Selective reporting (reporting bias) Low risk The study protocol was not available, but it
is clear that published reports include all ex-
pected outcomes
Other bias Low risk None was identified.
Hou 2013
Methods Four-arm randomised controlled trial
Participants Number of participants: 160 (conventional care group 40; invigorating and promoting
Qi group 40; blood-activating and damp-eliminating group 40; acupoint-combination
stimulation group 40)
Inclusion criteria: age > 60 years; patients who underwent major surgery, including
general surgeries, major gynaecological surgeries, limb fracture repairs, etc.; operative
duration > 2 hours; patients on postoperative bed rest who could not get out of bed; and
patients who signed the informed consent form
Exclusion criteria: inability to implement care measures in non-compliant patients; pa-
tients who dropped out halfway for various reasons; inability to implement interventions
in patients with lower limb infection; and inability to implement interventions among
patients in critical condition
Interventions Invigorating and promoting Qi group: postoperative routine care plus bilateral transcu-
taneous electrical stimulation at Taichong (LR 3) and Zusanli (ST 36) in two 20-minute
sessions per day (morning and afternoon) for 1 week
Blood-activating and damp-eliminating group: postoperative routine care plus bilateral
transcutaneous electrical stimulation at Yinlingquan (SP 9) and Sanyinjiao (SP 6) in two
20-minute sessions per day (morning and afternoon) for 1 week
Acupoint-combination stimulation group: postoperative routine care plus bilateral tran-
scutaneous electrical stimulation at a combination of 4 acupoints: Taichong (LR 3),
Zusanli (ST 36), Yinlingquan (SP 9), and Sanyinjiao (SP 6), in two 20-minute sessions
per day (morning and afternoon) for 1 week
Conventional care group: postoperative routine care, including observation, basic care,
catheter care, prevention and care of complications, and health education. In addition,
participants received help with raising the lower extremities and were given postoperative
symptomatic care
Outcomes DVT (diagnosed by Doppler ultrasound 7 days after surgery)
D-dimer levels
Changes in haemorheology: blood viscosity (including whole blood viscosity and plasma
viscosity)
Notes Data for the 3 NMES groups were combined in analyses.
Risk of bias
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Hou 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random numbers table was used.
Allocation concealment (selection bias) Unclear risk This was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding was reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No outcome data were missing.
Selective reporting (reporting bias) Low risk The study protocol was not available, but it is
clear that published reports include all expected
outcomes
Other bias High risk The study was Industry sponsored.
Kiudelis 2002
Methods Three-arm randomised controlled trial
Participants Number of participants: 54 (NMES group 18; GCS group 18; IPCD group 18)
Inclusion criteria: adult patients undergoing elective laparoscopic fundoplication
Exclusion criteria: not reported
Interventions NMES group: intermittent electrical calf muscle stimulation during operation
GCS group: GCS during operation
IPCD group: IPCD during operation
Outcomes Lower extremity venous blood velocity (measured by Doppler ultrasonography during
operation)
DVT (1 day after operation using venous occlusion plethysmography)
PE (1 day after operation using lung perfusion scintigraphy)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Kiudelis 2002 (Continued)
Random sequence generation (selection
bias)
Unclear risk This was not reported.
Allocation concealment (selection bias) Unclear risk This was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding was reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No outcome data were missing.
Selective reporting (reporting bias) Low risk The study protocol was not available, but it
is clear that published reports include all ex-
pected outcomes
Other bias Low risk None was identified.
Lindstrom 1982
Methods Three-arm randomised controlled trial
Participants Number of participants: 112 (stimulation group 37; control group 40; Dextran 40 group
35)
Inclusion criteria: patients who underwent major abdominal surgery
Interventions Stimulation group: optimised bilateral calf muscle stimulation with groups of impulses
during the entire operation.(strength 40 to 50 mA, impulse duration 50 ms; number
of impulses per group 6; impulse frequency within group 8 amp/s; group frequency 8
groups/min)
Control group: standard routine of the ward. Plasma and whole blood were given to
replace blood lost
Dextran 40 group: 500 mL Dextran 40 was given perioperatively and during the first
and third postoperative days
Outcomes DVT (Participants were screened by fibrinogen uptake test; whenever possible, a phle-
bography was performed.)
PE (diagnosed by pulmonary perfusion scintigraphy)
Total VTE
PE with DVT
Notes
Risk of bias
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Lindstrom 1982 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not reported.
Allocation concealment (selection bias) Unclear risk This was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding was reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No outcome data were missing.
Selective reporting (reporting bias) Low risk The study protocol was not available, but it
is clear that published reports include all ex-
pected outcomes
Other bias Low risk None was identified.
Merli 1988
Methods Three-arm randomised controlled trial
Participants Number of participants: 48 (NMES + low-dose heparin group 15; low-dose heparin
group 16; saline placebo group 17)
Inclusion criteria: patients with C2 to T11 motor complete and incomplete, preserved
motor, non-functional spinal cord injuries
Interventions NMES + low-dose heparin group: Tibialis anterior and gastrocnemius-soleus muscle
groups were stimulated bilaterally via 50-microsecond pulses given at 10 Hz with a 4-
second “on” and 8-second “off” cycle for 23 hours daily over a 28-day period + 5000 IU
heparin, given subcutaneously every 8 hours
Low-dose heparin group: 5000 IU heparin, given subcutaneously every 8 hours
Placebo: saline
Outcomes DVT (Venography was performed to confirm positive impedance plethysmography and/
or fibrinogen uptake tests.)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Merli 1988 (Continued)
Random sequence generation (selection
bias)
Unclear risk Data about randomisation were not reported.
Allocation concealment (selection bias) Unclear risk This was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants in control group received placebo
saline.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcomes were reported.
Selective reporting (reporting bias) Low risk The study protocol was not available, but it
is clear that published reports include all ex-
pected outcomes
Other bias Low risk None was identified.
Rosenberg 1975
Methods Quasi-randomised case-controlled trial
Participants Number of participants: 194 (NMES group 50; no prophylaxis group 89; low-dose
heparin group 55)
Inclusion criteria: Patients older than 40 years undergoing a major general surgical op-
eration for which they were expected to be in hospital for at least a week were eligible to
enter the trial
Exclusion criteria: No exclusions were made on the grounds of pre-existing cardiorespi-
ratory disease, peripheral vascular disease, or varicose veins; or previous history of throm-
bosis; but for technical reasons patients undergoing thyroidectomy, left mastectomy, and
peripheral arterial reconstruction were not studied
Interventions NMES group: intermittent electrical calf muscle stimulation during surgery, use of
Thrombophylactor (Rank Precision Industries Ltd.,Maidenhead, Berkshire, UK), which
delivers an interrupted direct current of 50 milliseconds duration every 5 seconds
Low-dose heparin group: heparin calciumadministered subcutaneously 5000 IU, the first
dose 2 hours before operation, then every 8 hours until the end of the sixth postoperative
day, or until the participant was fully mobile, whichever was longer
No prophylaxis group: leg exercises only
Outcomes DVT (The fibrinogen uptake test was performed on all participants for diagnosis.)
Notes
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Rosenberg 1975 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Randomisation into 3 groups was by month
of birth.
Allocation concealment (selection bias) High risk The study was a quasi-randomised trial, and
allocation was not adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding was reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No outcome data were missing.
Selective reporting (reporting bias) Low risk The study protocol was not available, but it
is clear that published reports include all ex-
pected outcomes
Other bias High risk This study was industry sponsored.
Velmahos 2005
Methods Two-arm randomised controlled trial
Participants Number of participants: 47 (NMES group 26; non-NMES group 21)
Inclusion criteria: trauma patients with Injury Severity Score > 9 who were admitted to
the intensive care unit and had a contraindication for prophylactic heparin; significant
head injury; operation for extensive organ injury; major retroperitoneal haematoma;
liver, spleen, or kidney injury higher than Grade II, managed non-operatively; other
injuries that at the discretion of the trauma surgeon were deemed to be associated with
a high likelihood for bleeding; anticipated survival for longer than 7 days; anticipated
hospital stay longer than 7 days; and randomisation within 24 hours of injury
Exclusion criteria: younger than 18 years; known allergy to contrast material, preclud-
ing use of venography, cardiac demand pacemakers, or other implanted stimulators or
implants containing metal parts within the area of treatment; spastic paralysis; local in-
fection at the site of application; and history or present evidence of venous thrombosis.
Trauma to the extremity was not an exclusion criterion
Interventions NMES group: two 30-minute sessions daily, 1 in themorning and 1 in the evening, using
the Lymphavision stimulator (Physiomed Elektromedizin AG, Schnaittach, Germany)
. Voltage was applied gradually (0 to 120 V) to obtain a slightly visible twitch of the
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Velmahos 2005 (Continued)
muscles. Stimuli 3 milliseconds long were used at a frequency of 1.75 Hz (105/min)
with inversion of polarity every 5 seconds
Non-NMES group: managed according to standard of care with no thromboprophylaxis
for as long as contraindications existed
Participants in both groups were allowed to have standard prophylaxis with subcutaneous
unfractionated or LMWH when the contraindication for its use was no longer present
Outcomes DVT (diagnosed by venography or Doppler ultrasound)
Venous blood flow velocity
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Type and method of randomisation are not
clearly described.
Allocation concealment (selection bias) Unclear risk Type and method of randomisation are not
clearly described, and allocation concealment
cannot be judged confidently
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding was reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing outcome data were not balanced in
numbers across intervention groups: 4 NMES
and 9 control participants were excluded from
analysis because of lack of outcome evaluation
(2 control participants died, 7 control partici-
pants and 1 NMES participant were transferred
to another hospital, and 2 NMES participants
refused to continue the study despite initial con-
sent)
Selective reporting (reporting bias) Low risk The study protocol was not available, but it is
clear that published reports include all expected
outcomes
Other bias High risk The study was industry sponsored.
CT: computed tomography.
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DVT: deep vein thrombosis.
GCS: graduated compression stockings.
IPCD: intermittent pneumatic compression devices.
LMWH: low molecular weight heparin.
ms: milliseconds.
NMES: neuromuscular electrical stimulation.
PE: pulmonary embolism.
US: ultrasound.
VTE: venous thromboembolism.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Browse 1970 Randomised legs instead of participants
Czyrny 2010 Included healthy individuals
Doran 1967 Randomised legs instead of participants
Doran 1970 Randomised legs instead of participants
Faghri 1998 Non-randomised, non-clinical study
Hou 2014 Study did not report outcomes defined in our review paper. Study authors were contacted to clarify if any of
our review outcomes had been measured, but no reply was received
Izumi 2014 Only 1 leg received NMES; the other leg received other methods of thromboprophylaxis
Jansen 1972 Investigated non-mechanical methods of prophylaxis
Kaplan 2002 Included healthy individuals
Lobastov 2014 Non-randomised study
Morita 2006 Included healthy individuals
NCT02425917 Trial was withdrawn before enrolment.
Nicolaides 1983 Randomised legs instead of participants
Ojima 2017 Investigated haemodynamic outcomes and was powered for these outcomes only
Pambianco 1995 NMES arm was terminated early in the pilot phase.
Rosengarten 1975 Investigated non-mechanical methods of prophylaxis
47Neuromuscular electrical stimulation for the prevention of venous thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Yilmaz 2016 Investigated haemodynamic outcomes only
NMES: neuromuscular electrical stimulation.
Characteristics of studies awaiting assessment [ordered by study ID]
NCT01835990
Methods Two-arm randomised controlled trial
Participants Inclusion criteria: diagnosis of trauma; age 18 years or older; contraindication to anticoagulation expected to last
longer than 3 days; projected hospitalisation longer than 3 days; and informed consent
Exclusion criteria: inability to wear either IPCs or geko™ (Sky Medical Technology Ltd, Newport, Vermont, USA)
on both legs; diagnosis of DVT within 1 month before assessment for enrolment; use of anticoagulant medication
within 24 hours of enrolment; leg circumference greater than 24 inches at the location where the geko™ device
would be secured to the leg; or presence of cardiac demand pacemaker
Interventions Intervention group: geko™
Comparator group: IPCs
Outcomes Incidence of DVT
Compliance
VTE
Tolerability
Venous and arterial physiological flow
Notes Study has been completed. Results of this study are not yet available
DVT: deep vein thrombosis.
IPC: intermittent pneumatic compression device.
VTE: venous thromboembolism.
Characteristics of ongoing studies [ordered by study ID]
ISRCTN95441725
Trial name or title Does theGeko™nerve stimulator reduce deep vein thrombosis (DVT) and improve healing in ankle fractures?
Methods Randomised controlled trial
Participants Adults aged 18 years or older, either sex, with closed ankle fractures that have required open reduction and
internal fixation; able to consent for themselves
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ISRCTN95441725 (Continued)
Interventions Each participant randomised into 1 of 2 groups, i.e. those who receive the stimulator for a 2-week period
postoperatively and those who do not
Outcomes DVT rate; time to union
Starting date 01/11/2012
Contact information Wirral University Teaching Hospital
Notes The study has been completed, but results have not yet been published. Study authors contacted, but no reply
NCT01935414
Trial name or title Geko™neuromuscular stimulator vs thromboembolism deterrent stockings (TEDS): DVT prevention study
Methods Open-label randomised controlled trial
Participants Inclusion criteria: aged 18 years or older; free of significant abnormal findings as determined by medical
history (specifically, absence of DVT or haematological disorders); no reported use of medications (prescribed
or over-the-counter, including herbal remedies) judged to be significant by the principal investigator during
the ten (10) days preceding enrolment; able to understand the patient information sheet and willing to sign
the written informed consent form; and able and willing to follow the protocol requirements
Interventions Intervention: continual Geko™ use post surgery for 48 hours, then for a minimum of 4 hours/d until
discharge
Control: continual use of TEDS stockings post surgery for 48 hours, then for a minimum of 4 hours/d until
discharge
Outcomes Presence of asymptomatic DVT assessed by duplex ultrasound
Starting date August 2013
Contact information matthew.womack@firstkindmedical.com
Notes
DVT: deep vein thrombosis.
NMES: neuromuscular electrical stimulation.
TEDS: thromboembolism deterrent stockings.
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D A T A A N D A N A L Y S E S
Comparison 1. NMES versus alternative prophylaxis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total DVT 6 415 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.60, 1.70]
2 Asymptomatic DVT 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Symptomatic DVT 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 PE 2 126 Odds Ratio (M-H, Fixed, 95% CI) 1.31 [0.38, 4.48]
5 Total VTE 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. NMES versus no prophylaxis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total DVT 4 576 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.23, 0.70]
2 Asymptomatic DVT 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Symptomatic DVT 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 PE 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Total VTE 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 3. NMES versus low-dose heparin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total DVT 2 194 Odds Ratio (M-H, Fixed, 95% CI) 2.78 [1.19, 6.48]
2 Asymptomatic DVT 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Symptomatic DVT 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
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Comparison 4. NMES versus Dextran 40
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total DVT 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 PE 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Total VTE 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 5. Combined NMES and low-dose heparin versus no prophylaxis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total DVT 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 6. Combined NMES and low-dose heparin versus low-dose heparin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total DVT 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 7. NMES versus GCS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total DVT 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 PE 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
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Comparison 8. NMES versus IPCD
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total DVT 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 PE 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 NMES versus alternative prophylaxis, Outcome 1 Total DVT.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 1 NMES versus alternative prophylaxis
Outcome: 1 Total DVT
Study or subgroup NMES Alternative methods Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rosenberg 1975 14/50 4/55 9.8 % 4.96 [ 1.51, 16.30 ]
Lindstrom 1982 5/37 7/35 22.2 % 0.63 [ 0.18, 2.19 ]
Bostrom 1986 5/40 5/49 14.0 % 1.26 [ 0.34, 4.69 ]
Merli 1988 1/15 16/33 33.2 % 0.08 [ 0.01, 0.65 ]
Kiudelis 2002 0/18 1/36 3.5 % 0.64 [ 0.02, 16.49 ]
Velmahos 2005 7/26 6/21 17.3 % 0.92 [ 0.26, 3.32 ]
Total (95% CI) 186 229 100.0 % 1.01 [ 0.60, 1.70 ]
Total events: 32 (NMES), 39 (Alternative methods)
Heterogeneity: Chi2 = 13.25, df = 5 (P = 0.02); I2 =62%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours NMES Favours alternative
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Analysis 1.2. Comparison 1 NMES versus alternative prophylaxis, Outcome 2 Asymptomatic DVT.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 1 NMES versus alternative prophylaxis
Outcome: 2 Asymptomatic DVT
Study or subgroup NMES Alternative methods Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bostrom 1986 5/40 4/49 1.61 [ 0.40, 6.43 ]
0.001 0.01 0.1 1 10 100 1000
Favours NMES Favours alternative
Analysis 1.3. Comparison 1 NMES versus alternative prophylaxis, Outcome 3 Symptomatic DVT.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 1 NMES versus alternative prophylaxis
Outcome: 3 Symptomatic DVT
Study or subgroup NMES Alternative methods Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bostrom 1986 0/40 1/49 0.40 [ 0.02, 10.07 ]
0.001 0.01 0.1 1 10 100 1000
Favours NMES Favours alternative
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Analysis 1.4. Comparison 1 NMES versus alternative prophylaxis, Outcome 4 PE.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 1 NMES versus alternative prophylaxis
Outcome: 4 PE
Study or subgroup NMES Alternative methods Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lindstrom 1982 6/37 4/35 77.7 % 1.50 [ 0.39, 5.84 ]
Kiudelis 2002 0/18 1/36 22.3 % 0.64 [ 0.02, 16.49 ]
Total (95% CI) 55 71 100.0 % 1.31 [ 0.38, 4.48 ]
Total events: 6 (NMES), 5 (Alternative methods)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours NMES Favours alternative
Analysis 1.5. Comparison 1 NMES versus alternative prophylaxis, Outcome 5 Total VTE.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 1 NMES versus alternative prophylaxis
Outcome: 5 Total VTE
Study or subgroup NMES Alternative methods Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lindstrom 1982 11/37 11/35 0.92 [ 0.34, 2.52 ]
0.01 0.1 1 10 100
Favours NMES Favours alternative
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Analysis 2.1. Comparison 2 NMES versus no prophylaxis, Outcome 1 Total DVT.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 2 NMES versus no prophylaxis
Outcome: 1 Total DVT
Study or subgroup NMES No prophylaxis Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rosenberg 1975 14/50 39/89 50.8 % 0.50 [ 0.24, 1.05 ]
Lindstrom 1982 5/37 12/40 25.1 % 0.36 [ 0.11, 1.16 ]
Goyal 2012 2/100 6/100 14.8 % 0.32 [ 0.06, 1.62 ]
Hou 2013 0/120 2/40 9.4 % 0.06 [ 0.00, 1.36 ]
Total (95% CI) 307 269 100.0 % 0.40 [ 0.23, 0.70 ]
Total events: 21 (NMES), 59 (No prophylaxis)
Heterogeneity: Chi2 = 1.82, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours NMES Favours no prophylaxis
Analysis 2.2. Comparison 2 NMES versus no prophylaxis, Outcome 2 Asymptomatic DVT.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 2 NMES versus no prophylaxis
Outcome: 2 Asymptomatic DVT
Study or subgroup NMES No prophylaxis Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Goyal 2012 2/100 6/100 0.32 [ 0.06, 1.62 ]
0.002 0.1 1 10 500
Favours NMES Favours no prophylaxis
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Analysis 2.3. Comparison 2 NMES versus no prophylaxis, Outcome 3 Symptomatic DVT.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 2 NMES versus no prophylaxis
Outcome: 3 Symptomatic DVT
Study or subgroup NMES No prophylaxis Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hou 2013 0/120 2/40 0.06 [ 0.00, 1.36 ]
0.001 0.01 0.1 1 10 100 1000
Favours NMES Favours no prophylaxis
Analysis 2.4. Comparison 2 NMES versus no prophylaxis, Outcome 4 PE.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 2 NMES versus no prophylaxis
Outcome: 4 PE
Study or subgroup NMES No prophylaxis Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lindstrom 1982 6/37 14/40 0.36 [ 0.12, 1.07 ]
0.01 0.1 1 10 100
Favours NMES Favours no prophylaxis
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Analysis 2.5. Comparison 2 NMES versus no prophylaxis, Outcome 5 Total VTE.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 2 NMES versus no prophylaxis
Outcome: 5 Total VTE
Study or subgroup NMES No prophylaxis Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lindstrom 1982 11/37 26/40 0.23 [ 0.09, 0.59 ]
0.01 0.1 1 10 100
Favours NMES Favours no prophylaxis
Analysis 3.1. Comparison 3 NMES versus low-dose heparin, Outcome 1 Total DVT.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 3 NMES versus low-dose heparin
Outcome: 1 Total DVT
Study or subgroup NMES Low-dose heparin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rosenberg 1975 14/50 4/55 41.1 % 4.96 [ 1.51, 16.30 ]
Bostrom 1986 5/40 5/49 58.9 % 1.26 [ 0.34, 4.69 ]
Total (95% CI) 90 104 100.0 % 2.78 [ 1.19, 6.48 ]
Total events: 19 (NMES), 9 (Low-dose heparin)
Heterogeneity: Chi2 = 2.30, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NMES Favours low-dose heparin
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Analysis 3.2. Comparison 3 NMES versus low-dose heparin, Outcome 2 Asymptomatic DVT.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 3 NMES versus low-dose heparin
Outcome: 2 Asymptomatic DVT
Study or subgroup NMES Low-dose heparin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bostrom 1986 5/40 4/49 1.61 [ 0.40, 6.43 ]
0.01 0.1 1 10 100
Favours NMES Favours low-dose heparin
Analysis 3.3. Comparison 3 NMES versus low-dose heparin, Outcome 3 Symptomatic DVT.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 3 NMES versus low-dose heparin
Outcome: 3 Symptomatic DVT
Study or subgroup NMES Low-dose heparin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bostrom 1986 0/40 1/49 0.40 [ 0.02, 10.07 ]
0.001 0.01 0.1 1 10 100 1000
Favours NMES Favours low-dose heparin
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Analysis 4.1. Comparison 4 NMES versus Dextran 40, Outcome 1 Total DVT.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 4 NMES versus Dextran 40
Outcome: 1 Total DVT
Study or subgroup NMES Dextran 40 Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lindstrom 1982 5/37 7/35 0.63 [ 0.18, 2.19 ]
0.01 0.1 1 10 100
Favours NMES Favours Dextran 40
Analysis 4.2. Comparison 4 NMES versus Dextran 40, Outcome 2 PE.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 4 NMES versus Dextran 40
Outcome: 2 PE
Study or subgroup NMES Dextran 40 Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lindstrom 1982 6/37 4/35 1.50 [ 0.39, 5.84 ]
0.01 0.1 1 10 100
Favours NMES Favours Dextran 40
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Analysis 4.3. Comparison 4 NMES versus Dextran 40, Outcome 3 Total VTE.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 4 NMES versus Dextran 40
Outcome: 3 Total VTE
Study or subgroup NMES Dextran 40 Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lindstrom 1982 11/37 11/35 0.92 [ 0.34, 2.52 ]
0.01 0.1 1 10 100
Favours NMES Favours Dextran 40
Analysis 5.1. Comparison 5 Combined NMES and low-dose heparin versus no prophylaxis, Outcome 1 Total
DVT.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 5 Combined NMES and low-dose heparin versus no prophylaxis
Outcome: 1 Total DVT
Study or subgroup
NMES +
low-dose
heparin No prophylaxis Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Merli 1988 1/15 8/17 0.08 [ 0.01, 0.76 ]
0.001 0.01 0.1 1 10 100 1000
Favours NMES + Low-dose heparin Favours no prophylaxis
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Analysis 6.1. Comparison 6 Combined NMES and low-dose heparin versus low-dose heparin, Outcome 1
Total DVT.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 6 Combined NMES and low-dose heparin versus low-dose heparin
Outcome: 1 Total DVT
Study or subgroup
NMES +
low-dose
heparin Low-dose heparin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Merli 1988 1/15 8/16 0.07 [ 0.01, 0.68 ]
0.001 0.01 0.1 1 10 100 1000
Favours NMES+low-dose hep Favours low-dose heparin
Analysis 7.1. Comparison 7 NMES versus GCS, Outcome 1 Total DVT.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 7 NMES versus GCS
Outcome: 1 Total DVT
Study or subgroup NMES GCS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kiudelis 2002 0/18 1/18 0.32 [ 0.01, 8.27 ]
0.002 0.1 1 10 500
Favours NMES Favours GCS
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Analysis 7.2. Comparison 7 NMES versus GCS, Outcome 2 PE.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 7 NMES versus GCS
Outcome: 2 PE
Study or subgroup NMES GCS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kiudelis 2002 0/18 1/18 0.32 [ 0.01, 8.27 ]
0.001 0.01 0.1 1 10 100 1000
Favours NMES Favours GCS
Analysis 8.1. Comparison 8 NMES versus IPCD, Outcome 1 Total DVT.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 8 NMES versus IPCD
Outcome: 1 Total DVT
Study or subgroup NMES IPCD Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kiudelis 2002 0/18 0/18 Not estimable
0.01 0.1 1 10 100
Favours NMES Favours IPCD
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Analysis 8.2. Comparison 8 NMES versus IPCD, Outcome 2 PE.
Review: Neuromuscular electrical stimulation for the prevention of venous thromboembolism
Comparison: 8 NMES versus IPCD
Outcome: 2 PE
Study or subgroup NMES IPCD Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kiudelis 2002 0/18 0/18 Not estimable
0.01 0.1 1 10 100
Favours NMES Favours IPCD
A D D I T I O N A L T A B L E S
Table 1. Neuromuscular electrical stimulation delivery in the included studies
Study Device Frequency (Hz) Pulse width Charge (mA) Voltage (V) Duration
Hou 2013 G6805-II 30-100 NR NR 6-15 7 days
(20 minutes twice/d)
Goyal 2012 VEINOPLUS NR NR NR 15-25 Only during surgery
Velmahos 2005 Lymphavision 1.75 3 ms NR 0-120 7-14 days
(30 minutes twice/d)
Kiudelis 2002 Mioritm 021 NR NR 50-100 NR Only during surgery
Merli 1988 NR 10 50 µs NR NR 28 days
(23 hours/d)
Bostrom 1986 NR 8 50 ms 40-50 NR 7 days
Lindstrom 1982 NR 8 50 ms 40-50 NR Only during surgery
Rosenberg 1975 Thrombophy-
lactor
NR 50 ms NR Adjustable Only during surgery
NR: rot reported.
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A P P E N D I C E S
Appendix 1. Glossary of terms for lay readers
Terms Meaning
Anticoagulant Having the effect of retarding or inhibiting the coagulation or clotting of
blood. Anticoagulants are a class of drugs that work to prevent coagulation
of blood
Compliance The action or fact of complying with treatment
Deep vein thrombosis (DVT) Formation of a blood clot in a deep vein - usually in the leg or pelvic veins
Endothelium The tissue that forms a single layer of cells lining various organs and cavities
of the body, especially the blood vessels, heart, and lymphatic vessels
Factor V Leiden A mutation of one of the clotting factors in the blood called factor V. This
mutation can increase the chance of developing abnormal blood clots (throm-
bophilia), usually in the veins
Graduated compression stockings (GCS) Elastic garments worn around the leg, compressing the limb. They help to
prevent the occurrence or further progression of venous disorders such as
oedema, phlebitis, and thrombosis
Hypercoagulable state An abnormality of blood coagulation that increases the risk of thrombosis
Incidence The occurrence, rate, or frequency of a disease
Intermittent pneumatic compression devices (IPCD) A therapeutic technique used inmedical devices that include an air pump and
inflatable auxiliary sleeves, gloves, or boots in a system designed to improve
venous circulation in the limbs of patients who suffer oedema or risk of DVT
or PE
Malignancy The state or presence of a malignant tumour; cancer
Morbidity The frequency of complications resulting from treatment or disease
Mortality The frequency of death resulting from treatment or disease
Neuromuscular electrical stimulation (NMES) Delivery of electrical impulses via electrodes to the skin over selected muscle
groups or nerves to induce an involuntary muscle contraction
Oedema Fluid retention in the body
Paraplagia Paralysis of the legs and lower body, typically caused by spinal injury or disease
Pathogenesis The manner of development of a disease
64Neuromuscular electrical stimulation for the prevention of venous thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Pharmacology The science of drugs including their origin, composition, pharmacokinetics,
therapeutic use, and toxicology
Prophylaxis Treatment given or action taken to prevent disease
Pulmonary embolism (PE) A sudden blockage in a lung artery that is caused by a blood clot that travels
to the lung from a vein in the leg
Subcutaneous Situated or applied under the skin
Thrombophilia An abnormal tendency to develop blood clots
Thrombosis Blood clots in blood vessels
Venous thromboembolism The occurrence DVT or PE or both
Appendix 2. CENTRAL search strategy
#1 MESHDESCRIPTOR Electric Stimulation EXPLODE ALL
TREES
1788
#2 (neuromusc* near3 stimul*):TI,AB,KY 495
#3 (electr* near3 stimul*):TI,AB,KY 7108
#4 (musc* near3 stimul*):TI,AB,KY 711
#5 (calf* near3 stimul*):TI,AB,KY 18
#6 (foot* near3 stimul*):TI,AB,KY 47
#7 (lower near3 stimul*):TI,AB,KY 168
#8 (limb near3 stimul*):TI,AB,KY 52
#9 (peroneal near3 stimul*):TI,AB,KY 37
#10 electromyostimul*:TI,AB,KY 66
#11 NMES:TI,AB,KY 242
#12 geko*:TI,AB,KY 8
#13 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR
#9 OR #10 OR #11 OR #12
7873
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(Continued)
#14 MESH DESCRIPTOR Thrombosis 1267
#15 MESH DESCRIPTOR Thromboembolism 921
#16 MESH DESCRIPTOR Venous Thromboembolism 258
#17 MESHDESCRIPTOR Venous Thrombosis EXPLODE ALL
TREES
2041
#18 (thrombus* or thrombopro* or thrombotic* or thrombolic*
or thromboemboli* or thrombos* or embol*):TI,AB,KY
18996
#19 MESH DESCRIPTOR Pulmonary Embolism EXPLODE
ALL TREES
748
#20 (PE or DVT or VTE):TI,AB,KY 4988
#21 ((vein* or ven*) near thromb*):TI,AB,KY 6717
#22 (blood near3 clot*):TI,AB,KY 2966
#23 (pulmonary near3 clot*):TI,AB,KY 5
#24 (lung near3 clot*):TI,AB,KY 4
#25 (venous near3 stasis):TI,AB,KY 128
#26 (venous near3 empty*):TI,AB,KY 10
#27 (blood near3 stasis):TI,AB,KY 453
#28 (blood near3 supply):TI,AB,KY 7412
#29 MESH DESCRIPTOR Hemodynamics EXPLODE ALL
TREES
46548
#30 MESH DESCRIPTOR Lower Extremity EXPLODE ALL
TREES WITH QUALIFIERS BS
1521
#31 (blood near3 flow):TI,AB,KY 12698
#32 hemodynamic*:TI,AB,KY 21594
#33 haemodynamic*:TI,AB,KY 5411
#34 fibrinoly*:TI,AB,KY 4822
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(Continued)
#35 #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR
#21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR
#28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34
93374
#36 #13 AND #35 709
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For completeness, we added the comparison of NMES versus no prophylaxis. Also, we considered ICU patients in the subgroup analysis
section.
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